SCHEDULE 13G/A: Tang Capital Entities Disclose 5.9% Passive Stake in ALX Oncology Holdings
Beneficial Ownership Report
Tang Capital Management, LLC and affiliated entities, including Kevin Tang, have filed an amended Schedule 13G, disclosing a combined beneficial ownership of 5.9% in ALX Oncology Holdings Inc. as of March 31, 2025.
Summary
- Tang Capital Management, LLC (TCM), Kevin Tang, Tang Capital Partners, LP (TCP), and Tang Capital Partners International, LP (TCPI) collectively beneficially own 3,158,265 shares of ALX Oncology Holdings Inc. Common Stock.
- This aggregate ownership represents 5.9% of ALX Oncology Holdings Inc.'s outstanding Common Stock.
- The percentage is based on 53,384,145 shares of Common Stock outstanding as of February 27, 2025, as reported in the Issuer's Annual Report on Form 10-K filed on March 6, 2025.
- TCM and Kevin Tang share voting and dispositive power over the entire 3,158,265 shares.
- TCP holds 1,722,175 shares, representing 3.2% of the class, with shared voting and dispositive power.
- TCPI holds 1,436,090 shares, representing 2.7% of the class, also with shared voting and dispositive power.
- The filing states that the securities were not acquired for the purpose of changing or influencing the control of the issuer, other than activities solely in connection with a nomination under Rule 14a-11.
Sentiment
Score: 5
Explanation: This is a factual disclosure of beneficial ownership and does not inherently convey positive or negative sentiment regarding the company's performance or outlook.
Future Outlook
NA
Industry Context
This filing is a standard disclosure of a significant passive ownership stake by an investment firm in a publicly traded biotechnology or pharmaceutical company, common in the investment landscape where institutional investors acquire positions for investment purposes.
Stakeholder Impact
- Shareholders: Provides transparency regarding significant ownership stakes by institutional investors, which can influence market perception and trading activity.
Key Dates
| Date | Description |
|---|---|
| 2025-02-27 | Date as of which 53,384,145 shares of Common Stock were outstanding, as reported in the Issuer's Form 10-K. |
| 2025-03-06 | Date ALX Oncology Holdings Inc. filed its Annual Report on Form 10-K with the SEC. |
| 2025-03-31 | Date of event which requires the filing of this Schedule 13G statement. |
| 2025-05-15 | Date of filing of this Schedule 13G Amendment No. 2. |
Keywords
ALX Oncology Holdings Inc., Tang Capital Management, Kevin Tang, Schedule 13G, Beneficial Ownership, Common Stock, Investment Firm, Passive Investment, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.